Join        Login             Stock Quote

Achillion Pharmaceuticals (ACHN) Posts Wider-Than-Expected Q3 Loss

 November 08, 2012 08:01 AM

(By Balaseshan) Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) reported a wider-than-expected loss in the third quarter due to costs incurred from clinical testing of its hepatitis C virus protease inhibitors.

Loss for the third quarter widened to $15.26 million or $0.20 per share from $10.44 million or $0.15 per share.

The company recognized no revenue for the third quarter, compared to about $64,000 last year.

Analysts, on average, polled by Thomson Reuters had expected a loss of $0.17 per share on revenue of $50,000 for the third quarter.

Research and development expenses increased to $12.6 million from $8.6 million, primarily due to increased expenses related to preclinical and clinical testing of ACH-3102, partially offset by decreased clinical trial expenses for sovaprevir, ACH-2684 and ACH-2928.

[Related -Insider Buying Achillion Pharmaceuticals, Inc. (ACHN) On The Verge Of FDA News And Technical Breakout?]

General and administrative expenses for the third quarter rose to $2.6 million from $1.9 million.

"Furthermore, with our strengthened balance sheet and continued progress with sovaprevir, our next-generation protease inhibitor, we believe that we are poised to begin all-oral, interferon-free combination studies evaluating our proprietary agents for the treatment of hepatitis C virus or HCV in the coming months," said Michael Kishbauch, Chief Executive of Achillion.

ACHN closed Wednesday's regular trading down 4.16% at $8.75. The stock has been trading between $5.12 and $12.95 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

A Snapback And 50% Retracement
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.